Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,457 people get REGN articles and Market Currents by email alert.
Get email alerts on REGN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
PR Newswire (May 8, 2013)
-
-
-
-
PR Newswire (May 3, 2013)
-
PR Newswire (May 3, 2013)
-
-
-
PR Newswire (Apr 18, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
at CNBC.com (May 14, 2013)
-
PR Newswire (May 8, 2013)
-
at MarketWatch.com (May 3, 2013)
-
PR Newswire (May 3, 2013)
-
PR Newswire (May 3, 2013)
-
at CNBC.com (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at CNBC.com (Apr 25, 2013)
-
at CNBC.com (Apr 24, 2013)
-
PR Newswire (Apr 18, 2013)
-
at CNBC.com (Apr 17, 2013)
-
PR Newswire (Apr 4, 2013)
-
at CNBC.com (Mar 28, 2013)
-
at CNBC.com (Mar 15, 2013)
-
at MarketWatch.com (Feb 19, 2013)
REGN vs. ETF Alternatives
Company Description
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. We currently have one marketed product: ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, February 11, 10:15 AM Regeneron (REGN) shares zoom up 8.5% and counting after resuming trading following news that Sanofi (SNY) aims to own up to $500M of stock in the company. The French firm says it could increase its stake in Regeneron "within (the) terms" of their partnership but has no plans to buy a controlling stake. Investors don't seem to be buying that line at the moment. Comment! [Healthcare, On the Move, Top Stories, Breaking News]
- Monday, February 11, 10:01 AM More on Sanofi (SNY +2.5%) buying Regeneron (REGN) shares: Sanofi's move follows speculation last year that it was interested in acquiring Regeneron. Sanofi is already Regeneron's largest shareholder, although the companies have a standstill agreement that prevents the French firm from acquiring more than 30% of Regeneron. The companies are also partners in Zaltrap for the treatment of colon cancer. REGN's shares are due to resume trading at 10:05 ET. (PR) 1 Comment [Breaking News, Healthcare, On the Move, Top Stories]
- Monday, February 11, 9:41 AM Sanofi (SNY) plans to acquire stock in Regeneron (REGN) through open market transactions and direct purchases from shareholders. As a result, Sanofi intends to own over $500M worth of voting shares by the end of the process. (PR) Comment! [Healthcare, Breaking News]
- Monday, February 11, 9:35 AM Trading Regeneron's (REGN) shares have been halted, pending news. Comment! [Healthcare]
- Tuesday, January 8, 9:39 AM Regeneron (REGN) -4.1%, although it's not obvious why. Q4 sales of Eylea, its eye treatment for wet age-related macular degeneration, were $276M. That's above estimates of $264.2M and brings the total for 2012 to $838M. Regeneron forecasts that U.S. sales will grow 50%, leading to annual revenue of $1.26B and already beating a Citigroup prediction that Eylea would generate peak annual sales of $1.1B in 2021. (Presentation for JPM conference) Comment! [On the Move, Healthcare, Earnings]
- Friday, January 4, 5:04 PM Regeneron Pharmaceuticals (REGN) says it's been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation to purchase up to 1M shares, or approximately 1.06%, of the outstanding float at a price of $161.25 per share. REGN] recommends that shareholders reject the offer because it's only a "mini-tender," priced below the current market and subject to numerous conditions. 1 Comment [Healthcare]
-
Friday, November 16, 2012, 5:40 PM
After-hours top gainers, as of 5:15 p.m.: GNOM +12.5%. GTAT +5.1%. SWFT +4.6%. KFY +4.5%. STRI +4.5%.
After-hours top losers: KWK -10.4%. REGN -9.7%. BPZ -9.4%. FLO -9.2%. NSM -8.7%. Comment! [On the Move] - Friday, November 16, 2012, 10:52 AM Sanofi (SNY -0.6%) and Regeneron (REGN +7.8%) report that the European Medicines Agency's CHMP has recommended granting marketing authorization for Zaltrap Injection for Intravenous Infusion in combination with FOLFIRI chemotherapy in adults with metastatic colorectal cancer. All that remains is for the European Commission to ratify the positive opinion from the CHMP to grant marketing authorization in all 27 E.U. member countries. A decision is expected in Q113. Comment! [Healthcare, On the Move, Global & FX]
- Tuesday, November 6, 2012, 3:45 AM A year after Lipitor lost its patent protection, a number companies are making headway on the next generation of medicines for reducing LDL, or "bad cholesterol." Much interest focuses on the cholesterol-regulating gene PCSK9 in the liver, with Amgen (AMGN) (see [[here]]) and Pfizer (PFE) yesterday presenting data showing that their drugs performed well in mid-stage trials. Sanofi (SNY) and partner Regeneron (REGN) announced a massive Phase III trial for their treatment. Comment! [Healthcare]
- Wednesday, October 24, 2012, 1:30 PM Regeneron (REGN +5.8%) gains after blowing away Q3 estimates earlier this morning. Total revenues soared over 300% Y/Y on strong demand for Eylea, REGN's injection for the treatment of neovascular age-related macular degeneration. Sales of the drug were up 26% from 2Q. The company boost its sales estimates again for the year, and notes that Eylea should further fuel growth in 2013 following recent FDA approval for its expanded use. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, October 24, 2012, 6:46 AM Regeneron Pharmaceuticals (REGN): Q3 EPS of $1.89 beats by $0.93. Revenue of $428M (+315% Y/Y) beats by $79M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, October 24, 2012, 12:05 AM Notable earnings before Wednesday’s open: AEP, ALXN, ATI, BA, BMY, CP, DAL, DPS, DTE, EAT, ECA, ELN, EMC, GD, GLW, HCBK, IACI, KMB, LCC, LL, LLY, LMT, LO, LVLT, MSI, NDAQ, NEE, NOC, NYB, OC, PVR, PX, RCI, REGN, RES, SAP, T, TMO, TROW, WYN Comment! [Earnings]
- Tuesday, October 23, 2012, 5:30 PM Notable earnings before Wednesday’s open: AEP, ALXN, ATI, BA, BMY, CP, DAL, DPS, DTE, EAT, ECA, ELN, EMC, GD, GLW, HCBK, IACI, KMB, LCC, LL, LLY, LMT, LO, LVLT, MSI, NDAQ, NEE, NOC, NYB, OC, PVR, PX, RCI, REGN, RES, SAP, T, TMO, TROW, WYN Comment! [Earnings]
- Thursday, October 4, 2012, 3:59 PM Regeneron (REGN +2.5%) finishes the day higher, after its price target was raised to $175 from $150 at RW Baird earlier today. The firm cites an upbeat survey for Eylea, and raises its estimates ahead of its Q3 results. Comment! [Healthcare]
- Friday, September 21, 2012, 2:59 PM Regeneron Pharmaceuticals (REGN -0.7%) announces that the FDA has approved Eylea Injection for the treatment of macular edema. The approval was based on data from Phase 3 studies which showed results for Eylea were superior to those for the sham control group for the primary endpoint. Comment! [Healthcare]
- Thursday, August 23, 2012, 3:21 PM Regeneron (REGN +3.4%) spikes higher once again today on takeover chatter involving Sanofi (SNY -1%). A spokesperson for the company declined to comment, on any takeover talks, noting that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies. SNY is currently REGN's largest shareholder, with a standstill agreement in place that prevents SNY from acquiring more than 30% of REGN. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
ZetaKap
3 Highly Liquid Large-Cap Stocks With Growth On The Horizon http://bit.ly/VcJhIT $AUY $EW $REGN @ZetaKap - View all 0 replies
-
Jim Van Meerten
REGN - 100% Barchart technical buy signal - 4 new highs and up 5.07% in the last month - Relative Strength Index 66.77% - View all 3 replies
-
-
-
Capitalist Bull
Leading Stocks Analysis Indicating Larger Correction Looms over the next few weeks. http://stks.co/eBKg AAPL GOOG REGN LNKD KORS JAZZ - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Capitalist Bull
Leading Stocks Analysis Updated, http://stks.co/gBM0. Indicates more upside 4 narrow band of stocks; $AAPL $GOOG $LNKD $FTK $REGN $Study - View all 0 replies
-
Capitalist Bull
Leading Stock Analysis Update, http://stks.co/k9PL, Hold strong positions..Sell excessive or lagging movers..Trades only. AAPL GOOG REGN - View all 0 replies
-
- View all 0 replies
-
Capitalist Bull
Traditional Technical Patterns completing & readying to #Breakout..$AAPL $GOOG $CLMT $REGN $RYL $BIDU $ALXN $ACT & more http://bit.ly/MwUXlb - View all 1 replies
-
LATEST REPLIES